{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:16Z","timestamp":1787293456624,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) compromises function and quality of life (QoL) and may precipitate chemotherapy modification. We evaluated longitudinal Patient-reported outcome measures (PROMs) during duloxetine-based CIPN management and explored clinical predictors of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This secondary longitudinal analysis was conducted within a randomized clinical cohort receiving duloxetine-based therapy for chemotherapy-induced peripheral neuropathy (CIPN). Of the patients included in the parent trial, 72 with analyzable patient-reported outcome data were included in the present analysis. PROMs were collected at baseline, week 4, and week 8 using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire\u2013Chemotherapy-Induced Peripheral Neuropathy 20-item module (EORTC QLQ- CIPN20), Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2013Neurotoxicity (FACT\/GOG-Ntx), Brief Pain Inventory (BPI), and Hamilton Anxiety Rating Scale HAM-A, and were analyzed using generalized estimating equations with multivariable adjustment. Instruments included EORTC QLQ-CIPN20 (0\u2013100; higher = worse), FACT\/GOG-Ntx (higher = better), Brief Pain Inventory (BPI) severity and interference (0\u201310; higher = worse), and. Hamilton Anxiety Rating Scale (HAM-A; higher = worse).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this PROM analysis, significant improvement was observed across CIPN symptoms, pain, anxiety, and QoL outcomes over 8 weeks. QLQ-CIPN20 total decreased at week 4 (MD \u221212.64) and week 8 (MD \u221223.81) versus baseline (both p &amp;lt; 0.001), with sensory (\u221213.71; \u221226.45), motor (\u221210.97; \u221222.06), and autonomic (\u22129.00; \u221218.44) domain reductions (all p &amp;lt; 0.001). FACT\/GOG-Ntx increased in week 4 (MD +6.42) and week 8 (MD +7.46) (p &amp;lt; 0.001), with no significant week 4-to-week eight increment. HAM-A decreased (\u22123.42; \u22126.77), while BPI severity (\u22121.55; \u22122.78) and interference (\u22121.26; \u22122.60) improved (all p &amp;lt; 0.001). Higher baseline pain predicted worse CIPN, lower QoL, and higher anxiety; metastatic disease and chemotherapy dose reduction were associated with poorer outcomes; missingness showed no strong baseline predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Duloxetine-based management was associated with rapid, sustained improvement in CIPN symptoms, pain, anxiety, and QoL over 8 weeks, supporting risk-stratified supportive care pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1853626","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:19Z","timestamp":1787290639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal patient-reported outcomes and predictors of improvement in chemotherapy-induced peripheral neuropathy a secondary analysis of a randomized trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Hager","family":"Salah","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Services, King Hamad University Hospital, Royal Medical Services","place":["Al saya, Bahrain"]},{"name":"Department of Clinical Pharmacy, Bahrain Oncology Center, Royal Medical Services","place":["Al saya, Bahrain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hassan","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Abdelrahman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasnaa","family":"Osama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa M.","family":"El-Kalaawy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Beni-Suef University","place":["Beni-Suef, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/nejmp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1200\/edbk_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00520-012-1428-5","article-title":"Impact of oxaliplatin-induced neuropathy: a patient perspective","volume":"20","author":"Bennett","year":"2012","journal-title":"Support. Care Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","article-title":"Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group\u2013Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols the spirit-pro extension","volume":"319","author":"Calvert","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/spcare-2022-003815","article-title":"Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis","volume":"13","author":"Chow","year":"2023","journal-title":"BMJ Support. Palliat. Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","article-title":"Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry","volume":"135","author":"Ezendam","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"B9","unstructured":"FACIT Group\n          \n          2016"},{"key":"B10","first-page":"1","article-title":"EORTC QLQ-C30 scoring manual the EORTC QLQ-C30 introduction","author":"Fayers","year":"2001"},{"key":"B11","first-page":"3","article-title":"Global cancer observatory: cancer today","author":"Ferlay","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fphar.2013.00156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","volume":"4","author":"Han","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s11136-017-1626-1","article-title":"Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)","volume":"26","author":"Kieffer","year":"2017","journal-title":"Qual. Life Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.6004\/jnccn.2022.7074","article-title":"Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes","volume":"21","author":"Li","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2424139","DOI":"10.1001\/jamanetworkopen.2024.24139","article-title":"Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy","volume":"7","author":"Li","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.31557\/APJCP.2022.23.5.1547","article-title":"Reliability and validity of the EORTC QLQ-CIPN20 (European Organization for research and treatment of cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20-Item scale) among Thai women with breast cancer undergoing taxane-bas","volume":"23","author":"Rattanakrong","year":"2022","journal-title":"Asian Pac J. Cancer Prev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2014.55.8361","article-title":"Cancer survivorship issues: life after treatment and implications for an aging population","volume":"32","author":"Rowland","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/ph19040553","article-title":"Efficacy and safety of duloxetine with Gabapentin or amitriptyline versus duloxetine monotherapy in chemotherapy-induced peripheral neuropathy","volume":"19","author":"Salah","year":"2026","journal-title":"Randomized Control. Trial Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for research and treatment of cancer QLQ-CIPN20 questionnaire organization for research and treatment of cancer QLQ-CIPN20 questionnaire","volume":"22","author":"Smith","year":"2013","journal-title":"Qual. Life Res."},{"key":"B25","first-page":"540","article-title":"Hamilton anxiety scale (HAM-A). Mental health and mental disorders: an encyclopedia of conditions, treatments, and well-being: volume 1: A-E: mental health and mental disorders: an encyclopedia of conditions, treatments, and well-being, 2015 being: volume 2: F-P","author":"Sperry","year":"2015","journal-title":"Ment. Health Ment. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2009.0078","article-title":"NCCN task force report: management of neuropathy in cancer","volume":"7","author":"Stubblefield","year":"2009","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"B27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","article-title":"Validation of the brief pain inventory for chronic nonmalignant pain","volume":"5","author":"Tan","year":"2004","journal-title":"J. Pain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1186\/s12885-025-14348-w","article-title":"Neurotoxicity associated with cancer chemotherapy: the first study in the Palestinian healthcare system","volume":"25","author":"Warrad","year":"2025","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1007\/s00520-019-04771-8","article-title":"Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy","volume":"27","author":"Yeo","year":"2019","journal-title":"Support Care Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1853626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:20Z","timestamp":1787290640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1853626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":29,"alternative-id":["10.3389\/fphar.2026.1853626"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1853626","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1853626"}}